[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Frenk et al., 1990 - Google Patents

Spinal paralysis and catalepsy induced by intrathecal injection of opioid agonists

Frenk et al., 1990

View PDF
Document ID
12033259726639459622
Author
Frenk H
Miller J
Johannessen J
Mayer D
Publication year
Publication venue
Pharmacology Biochemistry and Behavior

External Links

Snippet

The intrathecal administration of high (1.05 μmol) doses of D-Ala 2-Met 5-enkephalinamide (DAMA), D-Ala 2-Leu 5-enkephalinamide (DADLE), Try-D-Thr-Gly-Phe-Leu-Thr, MR2034- TA, dextrorphan tartrate, U50, 488H, levorphanol tartrate, methadone hydrochloride, and 1 …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION

Similar Documents

Publication Publication Date Title
Gosnell et al. Centrally administered opioid peptides stimulate saccharin intake in nondeprived rats
Simonnet et al. Opioid-induced hyperalgesia: abnormal or normal pain?
Yaksh et al. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen.
Stevens et al. Spinal infusion of opiate and alpha-2 agonists in rats: tolerance and cross-tolerance studies.
Tian et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat
Cador et al. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine
Spealman et al. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids.
Johanson The reinforcing properties of procaine, chloroprocaine and proparacaine in rhesus monkeys
Bornebusch et al. Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs
WO1997001351A1 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
Yamazaki et al. The opioid peptide analogue biphalin induces less physical dependence than morphine
Stevens et al. Hippocampal μ-receptors mediate opioid reinforcement in the CA3 region
Marchette et al. Heroin-and fentanyl-induced respiratory depression in a rat plethysmography model: potency, tolerance, and sex differences
Frenk et al. Spinal paralysis and catalepsy induced by intrathecal injection of opioid agonists
Rüedi-Bettschen et al. Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms
Ghorpade et al. Evidence of a role for N-methyl-D-aspartate (NMDA) receptors in the facilitation of tail withdrawal after spinal transection
Ferguson et al. GABAA receptor activation is involved in noncontingent shock inhibition of instrumental conditioning in spinal rats.
Ossenkopp et al. Nicotine-induced conditioned taste aversions are enhanced in rats with lesions of the area postrema
Tambeli et al. Contribution of spinal inhibitory receptors in heterosegmental antinociception induced by noxious stimulation
Olson et al. Behavioral effects after systemic injection of opiate peptides
Buerkle et al. Effect of continuous spinal remifentanil infusion on behaviour and spinal glutamate release evoked by subcutaneous formalin in the rat.
Picker et al. Differential cross-tolerance to mu and kappa opioid agonists in morphine-tolerant rats responding under a schedule of food presentation
Pittaway et al. CCK 8 analgesia and hyperalgesia after intrathecal administration in the rat: comparison with CCK-related peptides
EP1529057B1 (en) Biphalin derivatives and their analgesic applications
Cottrell et al. Hippocampal kindling-induced after-discharge and behavioural depression: immediate and long-term attenuation by opiate antagonists